Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase

1 May 2004

Abstract excerpt

The development of novel compounds that can effectively inhibit both wild type and the most consensus resistant strains of human immunodeficiency virus type 1 (HIV-1) is the primary focus in HIV disease management. Combination therapy, comprising at least three classes of drugs, has become the standard of care for acquired immunodeficiency syndrome (AIDS) or HIV-infected individuals. The drug cocktail can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 15134548
DOI: 10.2174/1568026043388484

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse TranscriptasePMID 15134548Read ↗

Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistance.Semantic proximity Read ↗

The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase.Semantic proximity Read ↗

Nucleoside and nucleotide inhibitors of HIV-1 replication.Semantic proximity Read ↗

Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNASemantic proximity Read ↗

Clinical Utility of Current NNRTIs and Perspectives of New Agents in This Class under DevelopmentSemantic proximity Read ↗

Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update.Semantic proximity Read ↗

Current HIV therapeutics: mechanistic and chemical determinants of toxicity.Semantic proximity Read ↗

Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus InfectionsSemantic proximity Read ↗

The Current Status of the NNRTI Family of Antiretrovirals Used Against HIV InfectionSemantic proximity Read ↗

Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase.Semantic proximity Read ↗

Structure, Synthesis and Inhibition Mechanism of Nucleoside Analogues as HIV‐1 Reverse Transcriptase Inhibitors (NRTIs)Semantic proximity Read ↗

Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.